b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">32002668</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>21</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>21</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1432-8798</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>165</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Mar</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Archives of virology</Title>\n                <ISOAbbreviation>Arch. Virol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Characterizing the antiviral effect of an ATR inhibitor on human immunodeficiency virus type 1 replication.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>683-690</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00705-020-04531-8</ELocationID>\n            <Abstract>\n                <AbstractText>In the search for new antiviral therapies against human immunodeficiency virus type 1 (HIV-1), several cellular targets are being investigated. Ataxia telangiectasia and Rad3-related protein (ATR) has been implicated in HIV-1 replication, namely during retroviral DNA integration. We studied the effect of the ATR inhibitor ETP-46464 on HIV-1 replication in peripheral blood mononuclear cells (PBMCs) and in the persistently HIV-1-infected cell line H61-D. After treatment with ETP-46464, a significant decrease in virus production was observed in both cell systems. Quantification of viral DNA forms in the acutely infected PBMCs suggests that inhibition could take place in the early phase of the viral life cycle before viral DNA integration. Moreover, after treatment of H61-D cells with 3\'-azido-3\'-deoxythymidine (AZT), which blocks new reverse transcription events, ETP-46464 decreased viral production, suggesting that inhibition of viral replication occurred in the late phase of the life cycle after viral DNA integration. A decrease in virus production after transfection of 293T cells with an HIV-1 infectious molecular clone also suggested that the effect of ETP-46464 is exerted at a post-integration step. We propose that ETP-46464 produces its inhibitory effect on HIV-1 replication by acting in both the early and late phases of the retroviral replication cycle. Thus, ATR could represent a new target for inhibition of HIV-1 replication.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Docando</LastName>\n                    <ForeName>F\xc3\xa9lix</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Unidad de Virolog\xc3\xada Molecular, Laboratorio de Referencia e Investigaci\xc3\xb3n en Retrovirus, Centro Nacional de Microbiolog\xc3\xada (CNM), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Casado</LastName>\n                    <ForeName>Concepci\xc3\xb3n</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Unidad de Virolog\xc3\xada Molecular, Laboratorio de Referencia e Investigaci\xc3\xb3n en Retrovirus, Centro Nacional de Microbiolog\xc3\xada (CNM), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pernas</LastName>\n                    <ForeName>Mar\xc3\xada</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Unidad de Virolog\xc3\xada Molecular, Laboratorio de Referencia e Investigaci\xc3\xb3n en Retrovirus, Centro Nacional de Microbiolog\xc3\xada (CNM), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mota-Biosca</LastName>\n                    <ForeName>Anna</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Unidad de Virolog\xc3\xada Molecular, Laboratorio de Referencia e Investigaci\xc3\xb3n en Retrovirus, Centro Nacional de Microbiolog\xc3\xada (CNM), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>L\xc3\xb3pez-Gal\xc3\xadndez</LastName>\n                    <ForeName>Cecilio</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Unidad de Virolog\xc3\xada Molecular, Laboratorio de Referencia e Investigaci\xc3\xb3n en Retrovirus, Centro Nacional de Microbiolog\xc3\xada (CNM), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Olivares</LastName>\n                    <ForeName>Isabel</ForeName>\n                    <Initials>I</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2347-5717</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Unidad de Virolog\xc3\xada Molecular, Laboratorio de Referencia e Investigaci\xc3\xb3n en Retrovirus, Centro Nacional de Microbiolog\xc3\xada (CNM), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. iolivar@isciii.es.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>(2016-77894-R) from MINECO (Spain)</GrantID>\n                    <Agency>MINECO</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>RD12/0017/0028</GrantID>\n                    <Agency>RIS-RETIC</Agency>\n                    <Country/>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>01</Month>\n                <Day>30</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Austria</Country>\n            <MedlineTA>Arch Virol</MedlineTA>\n            <NlmUniqueID>7506870</NlmUniqueID>\n            <ISSNLinking>0304-8608</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C000598436">ETP-46464</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D010078">Oxazines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.1</RegistryNumber>\n                <NameOfSubstance UI="C576597">ATR protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.1</RegistryNumber>\n                <NameOfSubstance UI="D064007">Ataxia Telangiectasia Mutated Proteins</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D064007" MajorTopicYN="N">Ataxia Telangiectasia Mutated Proteins</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010078" MajorTopicYN="N">Oxazines</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>05</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>01</Month>\n                <Day>18</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>1</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>1</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32002668</ArticleId>\n            <ArticleId IdType="doi">10.1007/s00705-020-04531-8</ArticleId>\n            <ArticleId IdType="pii">10.1007/s00705-020-04531-8</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'